Compare BioNano Genomics Inc (BNGO) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Halliburton Company — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Halliburton Company trades at $35.5 (market cap $29.59B). The key difference: Halliburton Company is far larger — about 2241.7× BioNano Genomics Inc's market cap, and Halliburton Company pays a 1.92% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | HAL | |
|---|---|---|
Market Cap | $13.20M | $29.59B |
Sector | Health | Energy |
52-Week High | $4.92 | $42.98 |
52-Week Low | $1.09 | $20.50 |
Enterprise Value | $15.81M | $35.67B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Halliburton (HAL) trades at $35.21, up 2.38% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a major contract win offshore Suriname highlight operational strength, though net income declined in 2025. The stock shows solid profitability with a 6.95% net margin and 14.56% ROE, supported by positive cash flow trends into 2026.
The outlook remains positive given analyst targets near $44.78 and ongoing energy sector tailwinds, but risks include oil price volatility and execution challenges. Earnings growth and contract execution are key catalysts for further upside, balancing macroeconomic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
